A few peptide residues in structurally important locations often determine biological functions of proteins implicated in the regulation of angiogenesis. We have shown recently that the short COOH-terminal segment PF-4(47-70) derived from platelet factor 4 (PF-4) is the smallest sequence that conserves potent antiangiogenic activity in vitro and in vivo. Here we show that modified COOH-terminal PF-4 peptides containing the sequence ELR (or related DLR), a critical domain present in proangiogenic chemokines, surprisingly elicit several times greater antiangiogenic potential than the original peptide. The modified peptides inhibit binding of iodinated vascular endothelial growth factor and fibroblast growth factor 2 to endothelial cell receptors, endothelial cell proliferation, migration, and microvessel assembly in the rat aortic ring model at lower doses than PF-4(47-70). On the differentiated chick chorioallantoic membrane, topical application of 40 micro g of modified peptides potently reduces capillary angiogenesis induced by vascular endothelial growth factor(165), a dose where peptide PF-4(47-70) was inactive. Established intracranial glioma in nude mice decreased significantly in size when treated locally with a total dose of 250 micro g of peptide PF-4(47-70)DLR (n = 10) compared with the same dose of the original PF-4(47-70) peptide (n = 10) or controls (n = 30). Tailored PF-4 peptides represent a new class of antiangiogenic agents with a defined mode of action and a strong in vivo activity.

Hagedorn, M., Zilberberg, L., Wilting, J., Canron, X., Carrabba, G., Giussani, C., et al. (2002). Domain swapping in a COOH-terminal fragment of platelet factor 4 generates potent angiogenesis inhibitors. CANCER RESEARCH, 62(23), 6884-6890.

Domain swapping in a COOH-terminal fragment of platelet factor 4 generates potent angiogenesis inhibitors

Carrabba, G;GIUSSANI, CARLO GIORGIO;
2002

Abstract

A few peptide residues in structurally important locations often determine biological functions of proteins implicated in the regulation of angiogenesis. We have shown recently that the short COOH-terminal segment PF-4(47-70) derived from platelet factor 4 (PF-4) is the smallest sequence that conserves potent antiangiogenic activity in vitro and in vivo. Here we show that modified COOH-terminal PF-4 peptides containing the sequence ELR (or related DLR), a critical domain present in proangiogenic chemokines, surprisingly elicit several times greater antiangiogenic potential than the original peptide. The modified peptides inhibit binding of iodinated vascular endothelial growth factor and fibroblast growth factor 2 to endothelial cell receptors, endothelial cell proliferation, migration, and microvessel assembly in the rat aortic ring model at lower doses than PF-4(47-70). On the differentiated chick chorioallantoic membrane, topical application of 40 micro g of modified peptides potently reduces capillary angiogenesis induced by vascular endothelial growth factor(165), a dose where peptide PF-4(47-70) was inactive. Established intracranial glioma in nude mice decreased significantly in size when treated locally with a total dose of 250 micro g of peptide PF-4(47-70)DLR (n = 10) compared with the same dose of the original PF-4(47-70) peptide (n = 10) or controls (n = 30). Tailored PF-4 peptides represent a new class of antiangiogenic agents with a defined mode of action and a strong in vivo activity.
Articolo in rivista - Articolo scientifico
Allantois; Amino Acid Sequence; Angiogenesis Inhibitors; Animals; Aorta; Brain Neoplasms; Cattle; Cell Division; Cell Movement; Chick Embryo; Chorion; Endothelial Growth Factors; Endothelium, Vascular; Female; Fibroblast Growth Factor 2; Glioma; Humans; In Vitro Techniques; Intercellular Signaling Peptides and Proteins; Lymphokines; Male; Mice; Mice, Nude; Molecular Sequence Data; Neovascularization, Pathologic; Neovascularization, Physiologic; Peptide Fragments; Platelet Factor 4; Protein Structure, Tertiary; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Xenograft Model Antitumor Assays
English
6884
6890
7
Hagedorn, M., Zilberberg, L., Wilting, J., Canron, X., Carrabba, G., Giussani, C., et al. (2002). Domain swapping in a COOH-terminal fragment of platelet factor 4 generates potent angiogenesis inhibitors. CANCER RESEARCH, 62(23), 6884-6890.
Hagedorn, M; Zilberberg, L; Wilting, J; Canron, X; Carrabba, G; Giussani, C; Pluderi, M; Bello, L; Bikfalvi, A
File in questo prodotto:
File Dimensione Formato  
Domain swapping PLT factor 4.pdf

Solo gestori archivio

Dimensione 291.86 kB
Formato Adobe PDF
291.86 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/148277
Citazioni
  • Scopus 48
  • ???jsp.display-item.citation.isi??? 43
Social impact